FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Medicines Agency decided that Firazyr's benefits are greater than its risks and recommended that it be given marketing authorisation.
Latvian: Eiropas Zāļu aģentūra nolēma, ka ieguvums, lietojot Firazyr, pārsniedz šo zāļu radīto risku, un ieteica izsniegt šo zāļu reģistrācijas apliecību.
English: Each pre-filled syringe of Firazyr contains 30 mg icatibant in 3 ml.
Latvian: Katra Firazyr pilnšļirce satur 30 mg ikatibanta 3 ml.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Firazyr can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Latvian: Retu slimību ārstēšanai paredzēto zāļu komitejas atzinuma kopsavilkums par Firazyr ir atrodams aģentūras tīmekļa vietnē: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Because the number of patients with angioedema is low, the disease is considered ‘rare', and Firazyr was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 February 2003.
Latvian: Tā kā angioedēmas pacientu skaits ir mazs, šo slimību uzskata par „retu“, un 2003. gada 17. februārī Firazyr tika piešķirts reti sastopamu slimību ārstēšanai paredzētu zāļu statuss.
English: Patients' symptoms were relieved on average 2 to 2.5 hours after receiving Firazyr, compared with 12 hours for tranexamic acid in one study and 4.6 hours for placebo in the other study.
Latvian: Pacienti sajuta atvieglojumu vidēji pēc 2 līdz 2,5 stundām pēc Firazyr saņemšanas, salīdzinot ar 12 stundām pēc traneksāmskābes saņemšanas vienā pētījumā un pēc 4,6 stundām pēc placebo saņemšanas otrā pētījumā.
English: What is Firazyr and what is it used for?
Latvian: Kas ir Firazyr un kāpēc tās lieto?
English: Why is Firazyr approved?
Latvian: Kāpēc Firazyr tika apstiprinātas?
English: Firazyr is a medicine used to treat the symptoms of attacks of hereditary angioedema in adults, adolescents and children aged over 2 years.
Latvian: Firazyr ir zāles, ko lieto, lai ārstētu iedzimtās angioedēmas tūskas lēkmju simptomus pieaugušajiem, pusaudžiem un bērniem, kas vecāki par diviem gadiem.
English: Patients with angioedema have attacks of swelling that can occur anywhere in the body, such as in the face or limbs, or around the gut, causing discomfort and pain.
Latvian: Pacientiem ar angioedēmu ir tūskas lēkmes, kas var rasties jebkurā ķermeņa vietā, piemēram, uz sejas vai ekstremitātēm, vai ap zarnām, izraisot nepatīkamu sajūtu un sāpes.
English: Firazyr is used in patients whose angioedema is linked to naturally low levels of a protein called ‘C1 esterase inhibitor'.
Latvian: Firazyr indicē pacientiem, kuru angioedēma ir saistīta ar dabiski zemu proteīna C1 esterāzes inhibitora līmeni.
English: The active substance in Firazyr, icatibant, blocks the receptors that bradykinin normally attaches to.
Latvian: Firazyr aktīvā viela ikatibants bloķē receptorus, pie kuriem bradikinīns parasti piesaistās.
English: In another study involving 22 adolescents and children aged over 2 years with hereditary angioedema, symptoms improved on average 1 hour after the patients received Firazyr.
Latvian: Citā pētījumā, iesaistot 22 pusaudžus un bērnus, kas vecāki par diviem gadiem, ar iedzimtu angioedēmu, simptomi mazinājās vidēji vienu stundu pēc tam, kad pacienti saņēma Firazyr.
English: What benefits of Firazyr have been shown in studies?
Latvian: Kādas bija Firazyr priekšrocības šajos pētījumos?
English: In both studies, the time it took for symptoms to improve was shorter for patients taking Firazyr than the comparator medicine.
Latvian: Abos pētījumos laiks, kādā pacienta simptomi mazinājās, bija īsāks tiem pacientiem, kuri lietoja Firazyr, salīdzinājumā ar pacientiem, kas lietoja salīdzinājuma zāles.
English: The most common side effects with Firazyr (seen in more than 1 patient in 10) are injection site reactions including erythema (redness), swelling, burning, itching and pain at injection sites.
Latvian: Visbiežākās Firazyr blakusparādības (kas var rasties vairāk nekā 1 no 10 pacientiem) ir reakcijas injekcijas vietā, tostarp eritēma (sārtums), pietūkums, dedzināšana, nieze un sāpes injekcijas vietā.
English: For practical information about using Firazyr, patients should read the package leaflet or contact their doctor or pharmacist.
Latvian: Lai saņemtu praktisku informāciju par Firazyr lietošanu, pacientiem jāizlasa zāļu lietošanas instrukcija vai jāsazinās ar ārstu vai farmaceitu.
English: Attacks of hereditary angioedema can be life threatening when they involve the throat.
Latvian: Iedzimtās angioedēmas tūskas lēkmes var apdraudēt dzīvību, ja tās skar rīkli.
English: For more information about treatment with Firazyr, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Latvian: Lai saņemtu sīkāku informāciju par ārstēšanu ar Firazyr, izlasiet zāļu lietošanas instrukciju (kas arī ir EPAR daļa) vai sazinieties ar ārstu vai farmaceitu.
English: The first study compared Firazyr with tranexamic acid (another medicine for hereditary angioedema) in 74 patients, and the second study compared Firazyr with placebo (a dummy treatment) in 56 patients.
Latvian: Pirmajā pētījumā iesaistot 74 pacientus, Firazyr salīdzināja ar traneksāmskābi (citām zālēm, ko lieto iedzimtās angioedēmas ārstēšanā), un otrajā pētījumā iesaistot 56 pacientus, Firazyr salīdzināja ar placebo (fiktīvu ārstēšanu).
English: Firazyr was found to relieve swelling in the skin and abdomen, as well as swelling of the throat.
Latvian: Tika konstatēts, ka Firazyr mazina ādas un vēdera, kā arī rīkles pietūkumu.
English: How does Firazyr work?
Latvian: Kā Firazyr darbojas?
English: What are the risks associated with Firazyr?
Latvian: Kāds risks pastāv, lietojot Firazyr?
English: Firazyr was also found effective among patients included in the two studies who had attacks of angioedema that affected the throat.
Latvian: Firazyr efektivitāti pierādīja arī tiem abos pētījumos iesaistītajiem pacientiem, kuriem bija angioedēmas tūskas lēkmes, kas skāra kaklu.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Firazyr have been included in the summary of product characteristics and the package leaflet.
Latvian: Zāļu aprakstā un lietošanas instrukcijā tika ietverti ieteikumi un piesardzības pasākumi, kas jāievēro veselības aprūpes speciālistiem un pacientiem, lai garantētu drošu un efektīvu Firazyr lietošanu.
English: Firazyr contains the active substance icatibant.
Latvian: Firazyr satur aktīvo vielu ikatibantu.
English: How is Firazyr used?
Latvian: Kā lieto Firazyr?
English: The medicine is given by injecting it slowly under the skin, preferably in the abdomen (belly).
Latvian: Firazyr ievada lēnas zemādas injekcijas veidā, vēlams, vēderā.
English: Firazyr was found effective in two main studies in adults with hereditary angioedema involving the skin or the abdomen.
Latvian: Firazyr efektivitāti pierādīja divos pamatpētījumos, iesaistot ādas vai vēdera iedzimtās angioedēmas pacientus.
English: Patients with hereditary angioedema have high levels of a substance called ‘bradykinin', which is involved in causing inflammation and swelling.
Latvian: Iedzimtās angioedēmas pacientiem ir augsta tā dēvētā „bradikinīna” koncentrācija.
English: Firazyr icatibant
Latvian: Firazyr ikatibants
English: For the list of all side effects and restrictions with Firazyr, see the package leaflet.
Latvian: Pilnu visu ziņoto blakusparādību sarakstu, lietojot Firazyr, skatīt zāļu lietošanas instrukcijā.
English: This summary was last updated in 11/2013.
Latvian: Šo kopsavilkumu pēdējo reizi atjaunināja 11.2013.
English: The full EPAR for Vitekta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Latvian: Pilns Vitekta EPAR teksts ir atrodams aģentūras tīmekļa vietnē: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Vitekta.
Latvian: Šis ir Eiropas Publiskā novērtējuma ziņojuma (EPAR) kopsavilkums par Vitekta.
English: Vitekta is available as tablets (85 and 150 mg); the recommended dose is one tablet a day, taken with food.
Latvian: Vitekta ir pieejamas tablešu veidā (85 mg un 150 mg); ieteicamā deva ir viena tablete dienā kopā ar uzturu.
English: Vitekta must not be used with certain other medicines that may reduce its effectiveness or increase the risks of resistance.
Latvian: Vitekta nedrīkst lietot kopā ar noteiktām citām zālēm, kas var mazināt to efektivitāti vai palielināt rezistences risku.
English: It is not intended to provide practical advice on how to use Vitekta.
Latvian: Tas nav paredzēts kā praktiski ieteikumi par Vitekta lietošanu.
English: What is Vitekta and what is it used for?
Latvian: Kas ir Vitekta un kāpēc tās lieto?
English: When the enzyme is blocked, the virus cannot reproduce normally, slowing down the spread of infection.
Latvian: Kad enzīms ir bloķēts, vīruss nespēj normāli vairoties, kā rezultātā palēninās infekcijas izplatīšanās.
English: The Committee also noted that there is a significant potential for interactions with other medicines, and this has been reflected in the product information.
Latvian: Komiteja arī ņēma vērā, ka ir iespējama nozīmīga mijiedarbība ar citām zālēm, un tā ir atspoguļota zāļu aprakstā.
English: A risk management plan has been developed to ensure that Vitekta is used as safely as possible.
Latvian: Lai nodrošinātu iespējami nekaitīgu Vitekta lietošanu, ir izstrādāts riska pārvaldības plāns.
English: After 48 weeks, around 59% of patients treated with Vitekta (207 out of 351) responded to treatment compared with around 58% of patients treated with
Latvian: Pēc 48 nedēļām uz ārstēšanu reaģēja aptuveni 59 % ar Vitekta ārstēto pacientu (207 no 351), salīdzinot ar aptuveni 58 % ar raltegravīru ārstēto pacientu (203 no 351).
English: What measures are being taken to ensure the safe and effective use of
Latvian: Kas tiek darīts, lai nodrošinātu nekaitīgu un efektīvu Vitekta lietošanu?
English: The main measure of effectiveness was based on the reduction in the levels of HIV in the blood (viral load).
Latvian: Galvenais efektivitātes rādītājs bija balstīts uz HIV daudzuma asinīs (vīrusu slodzes) samazināšanos.
English: Vitekta has been investigated in one main study involving 712 patients with HIV-1 who had not been treated before with an integrase inhibitor.
Latvian: Vitekta pētīja vienā pamatpētījumā, iesaistot 712 pacientus ar HIV-1 infekciju, kuri iepriekš nebija ārstēti ar integrāzes inhibitoru.
English: Vitekta does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Latvian: Ar Vitekta nevar izārstēt HIV-1 infekciju vai AIDS, bet tas var aizkavēt imūnsistēmas bojājumu un ar AIDS saistītu infekciju un slimību rašanos.
English: Regarding the safety profile of the medicine, this was not considered of concern, with side effects comparable to other similar medicines.
Latvian: Zāļu drošības profils neradīja bažas, jo to blakusparādības bija līdzīgas kā citām līdzīgām zālēm.
English: Patients who attained a viral load of less than 50 copies/ml after 48 weeks of treatment were considered to have responded to treatment.
Latvian: Pastāvēja uzskats, ka pacientiem, kuriem pēc 48 ārstēšanas nedēļām vīrusu slodze ir mazāka par 50 vienībām/ml, ir atbildes reakcija pret ārstēšanu.
English: The choice of dose of Vitekta depends on which other medicines it is given with.
Latvian: Vitekta devas izvēle ir atkarīga no tā, ar kādām citām zālēm tās kopā lieto.
English: In this study, Vitekta was at least as effective as raltegravir (another integrase inhibitor) when taken in combination with other anti-HIV medicines.
Latvian: Šajā pētījumā Vitekta bija vismaz tikpat efektīvs līdzeklis kā raltegravīrs (cits integrāzes inhibitors), lietojot kopā ar citām pret HIV infekciju vērstām zālēm.
English: Vitekta is taken either at the same time as a once-daily protease inhibitor, or with the first dose of a twice-daily protease inhibitor.
Latvian: Vitekta lieto vai nu vienlaicīgi ar vienreiz dienā lietotu proteāzes inhibitoru, vai kopā ar divreiz dienā lietota proteāzes inhibitora pirmo devu.
English: It blocks an enzyme called integrase, which is involved in a step in the reproduction of HIV.
Latvian: Tas bloķē enzīmu integrāzi, kas ir iesaistīta HIV vairošanās posmā.
English: The most common side effects with Vitekta (which may affect up to 1 in 10 people) are headache, abdominal pain (stomach ache), diarrhoea, vomiting, nausea (feeling sick), rash, fatigue (tiredness).
Latvian: Visbiežāk novērotās Vitekta blakusparādības (1 līdz 10 pacientiem) ir galvassāpes, vēdersāpes, caureja, vemšana, slikta dūša (nelabums), izsitumi, nespēks (nogurums).
English: It is used in combination with ‘protease inhibitor' medicines taken together with ritonavir, and with other anti-HIV medicines in patients whose disease is not expected to be resistant
Latvian: Šīs zāles lieto kombinācijā ar proteāzes inhibitoriem, kurus lieto kopā ar ritonavīru, un citām pret HIV infekciju vērstām zālēm pacientiem, kuriem nav paredzama rezistence pret elvitegravīru.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Vitekta's benefits are greater than its risks and recommended that it be approved for use in the EU.
Latvian: CHMP nolēma, ka pacientu ieguvums, lietojot Vitekta, pārsniedz šo zāļu radīto risku, un ieteica apstiprināt tās lietošanai ES.
English: Vitekta is an antiviral medicine that contains the active substance elvitegravir.
Latvian: Vitekta ir pretvīrusu zāles, kas satur aktīvo vielu elvitegravīru.
English: For more information about treatment with Vitekta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Latvian: Plašāka informācija par ārstēšanu ar Vitekta atrodama zāļu lietošanas instrukcijā (kas arī ir EPAR daļa) vai sazinoties ar ārstu vai farmaceitu.
English: The CHMP concluded that the benefits of Vitekta in reducing the levels of HIV in the blood had been clearly shown in studies.
Latvian: CHMP secināja, ka šajos pētījumos skaidri pierādīti Vitekta sniegtie ieguvumi, pazeminot HIV līmeni asinīs.
English: What benefits of Vitekta have been shown in studies?
Latvian: Kādas bija Vitekta priekšrocības šajos pētījumos?
English: For practical information about using Vitekta, patients should read the package leaflet or contact their
Latvian: Lai iegūtu praktisku informāciju par Vitekta lietošanu, pacientiem jāizlasa zāļu lietošanas instrukcija vai jāsazinās ar ārstu vai farmaceitu.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vitekta, including the appropriate precautions to be followed by healthcare
Latvian: Pamatojoties uz šo plānu, Vitekta zāļu aprakstā ietverta drošuma informācija, kā arī lietošanas instrukcija, tostarp attiecīgi piesardzības pasākumi, kas jāievēro veselības aprūpes speciālistiem un pacientiem.
English: It is used to treat adults with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immunodeficiency syndrome (AIDS).
Latvian: Tās lieto, lai ārstētu pieaugušos, kuriem ir 1. tipa cilvēka imūndeficīta vīrusa (HIV-1) infekcija.
English: The European Commission granted a marketing authorisation valid throughout the European Union for
Latvian: Eiropas Komisija 2013. gada 13. novembrī izsniedza Vitekta reģistrācijas apliecību, kas derīga visā Eiropas Savienībā.
English: What are the risks associated with Vitekta?
Latvian: Kāds risks pastāv, lietojot Vitekta?
English: The active substance in Vitekta, elvitegravir, is a type of antiviral agent called an ‘integrase inhibitor'.
Latvian: Vitekta aktīvā viela elvitegravīrs ir pretvīrusu līdzeklis, ko dēvē par integrāzes inhibitoru.
English: Vitekta can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infections.
Latvian: Ārstēšana jāsāk ārstam, kuram ir pieredze HIV infekciju ārstēšanā.
English: For the full list of all side effects reported with Vitekta, see the package leaflet.
Latvian: Pilns visu Vitekta izraisīto blakusparādību saraksts ir atrodams zāļu lietošanas instrukcijā.
English: For further information, see
Latvian: Cita informācija par Vitekta
English: Invented name Strength Pharmaceutical Form
Latvian: Stiprums Zâïu forma
English: Route of administration
Latvian: Ievadîðanas veids
English: Available data are described in sections 4.8, 5.1 and 5.2.
Latvian: Pieejamie dati aprakst ti apakšpunktos 4.8, 5.1 un 5.2.
English: Do not pass it on to others.
Latvian: Nedodiet t s citiem.
English: If this applies to you, the use of Diovan is not recommended.
Latvian: Ja tas attiecas uz Jums, Diovan lietošana nav ieteicama.
English: Biotransformation:
Latvian: Biotransform cija:
English: To do this:
Latvian: Lai to paveiktu nepieciešams:
English: If you forget to take a dose, take it as soon as you remember.
Latvian: Ja atceraties par aizmirsto devu, ie emiet to, tikl dz atceraties.
English: • if you have recently undergone kidney transplantation (received a new kidney).
Latvian: • Ja Jums nesen bijusi nieru transplant cija (J s sa m t jaunu nieri).
English: How much to take
Latvian: Cik daudz z u lieto
English: Primary hyperaldosteronism
Latvian: Prim rais hiperaldosteronisms
English: The half-life of valsartan is 6 hours.
Latvian: Valsart na sadal šan s pusperiods ir 6 stundas.
English: • if you suffer from aldosteronism.
Latvian: • Ja J s ciešat no aldosteronisma.
English: Hypotension, Orthostatic hypotension
Latvian: Hipotensija, ortostatisk hipotensija
English: Poloxamer (188)
Latvian: Poloksam rs (188)
English: A press in bottle adapter:
Latvian: Iespiežams pudeles adapters:
English: Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA03
Latvian: Farmakoterapeitisk grupa: angiotenz na II antagonists, monoprepar ti, AT kods: C09CA03
English: Hypertension (paediatric population)
Latvian: Hipertensija (pediatrijas pacientiem)
English: • Keep this leaflet.
Latvian: • Saglab jiet šo instrukciju!
English: Valsartan does not undergo any noteworthy biotransformation.
Latvian: Valsart ns netiek pak auts izteiktai biotransform cijai.
English: High blood pressure increases the risk of heart attacks.
Latvian: Augsts asinsspiediens paaugstina miokarda infarkta risku.
English: 4.3 Contraindications
Latvian: 4.3 Kontrindik cijas
English: If you have further questions on the use of this product, ask your doctor or pharmacist.
Latvian: Ja Jums ir k di jaut jumi par š produkta lietošanu, jaut jiet savam rstam vai farmaceitam.
English: Drink the entire solution right away.
Latvian: 17. Izdzeriet visu š dumu uzreiz.
English: Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.
Latvian: Valsart ns izteikti saist s ar seruma olbaltumiem (94-97%), galvenok rt seruma album nu.
English: 4.1 Therapeutic indications
Latvian: 4.1 Terapeitisk s indik cijas
English: • that you insert into the neck of the bottle.
Latvian: • tas Jums j ievieto pudeles kakli .
English: [To be completed nationally]
Latvian: [Aizpilda nacion li]
English: Asthenia, Fatigue
Latvian: V rgums, nogurums
English: For a full list of excipients, see section 6.1.
Latvian: Pilnu pal gvielu sarakstu skat t apakšpunkt 6.1.
English: • spinning sensation (vertigo)
Latvian: • griešan s saj ta (vertigo)
English: There is currently no experience on the safe use of Diovan in patients who have recently undergone kidney transplantation.
Latvian: Nieru transplant cija Pašlaik nav pieredzes par Diovan droš bu pacientiem, kuriem nesen veikta nieru transplant cija.
English: Hypersensitivity including serum sickness
Latvian: Hipersensitivit te, tostarp seruma slim ba
English: • if you have lost a lot of fluid (dehydration) caused by diarrhoea, vomiting, or high doses of water tablets (diuretics).
Latvian: • Ja esat zaud jis lielu š idruma daudzumu (dehidrat cija), ko izrais jusi caureja, vemšana vai lielas tablešu dens izvad šanai (diur tiku) devas.
English: INFORMATION IN BRAILLE [To be completed nationally]
Latvian: 16. INFORMCIJA BRAILA RAKST [Aizpilda nacionli]
English: Nausea, Diarrhoea
Latvian: Nelabums, diareja
English: • if you have severe heart disease, your doctor may check your kidney function.
Latvian: • Ja Jums ir cita smaga sirds slimba, rsts var prbaudt Jsu nieru funkcijas.
English: • then, push the plunger all the way back in so that it is empty again.
Latvian: • tad izspiest virzuli l dz galam, lai š irce peror lai ievad šanai atkal b tu tukša.
English: The protocol of the study will be submitted by the applicant in the second quarter of 2010 for agreement with the CHMP with input from the PDCO.
Latvian: P t juma protokolu pieteikuma iesniedz js iesniegs 2010. gada otraj ceturksn , lai saska otu ar CHMP un iestr d tu PDCO ieteikumus.
English: - Post-myocardial infarction and/or heart failure (studied in adult patients only)
Latvian: - Miokarda infarktu p rcietušie un/vai sirds mazsp jas pacienti (p t ts vien gi pieaugušiem pacientiem)
English: WHAT DIOVAN IS AND WHAT IT IS USED FOR
Latvian: KAS IR DIOVAN UN K DAM NOL KAM TO LIETO
English: The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4).
Latvian: Nav ieteicama angiotenz na II receptoru antagonistu (AIIRA) lietošana gr tniec bas pirm trimestra laik (skat t apakšpunktu 4.4).
English: If you forget to take Diovan
Latvian: Ja esat aizmirsis lietot Diovan
English: Paediatric population
Latvian: Pediatrijas pacienti
English: Note: You may not be able to push the bottle adapter down fully but this does not matter as it will be forced into the bottle when you screw the cap back on.
Latvian: Piez me: Varb t J s nevar sit nospiest pudeles adapteri l dz galam uz leju, bet tas tiks iespiests pudel , uzskr v jot atpaka v ci u.
English: 2 and 4, rue Lionel Terray
Latvian: Novartis Pharma S.A.S. 2 and 4, rue Lionel Terray
English: • Submit a Risk Management Plan (or its update) for Diovan at National level, taking into account the new paediatric data and the CHMP recommendations.
Latvian: • iesniegt Diovan riskvad bas pl nu (vai t atjaunin to versiju) valstu l men , emot v r jaun kos pediatrijas datus un CHMP ieteikumus.
English: Each ml solution contains 0.3 g sucrose, 1.62 mg methyl parahydroxybenzoate (E218) and 5 mg poloxamer (188)
Latvian: Viens ml š duma iekš gai lietošanai satur 0,3 g saharozes, 1,62 mg metilparahidroksibenzo ta (E218) un 5 mg poloksam ra (188)
English: Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor.
Latvian: Valsart nam nav da jas AT1 receptoru agonista iedarb bas un tam ir daudz liel ka afinit te (apm ram 20 000 reizes) pret AT1 nek pret AT2 receptoriem.
English: Take Diovan solution once a day
Latvian: Lietojiet Diovan š dumu iekš gai lietošanai vienu reizi dien
English: Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium.
Latvian: Turkl t vienlaic ga angiotenz na II antagonistu un NPL lietošana var rad t paaugstin tu nieru funkcijas pasliktinšans risku un paaugstint klija lmeni serum.
English: High blood pressure increases the workload on the heart and arteries.
Latvian: Augsts asinsspiediens palielina sirds un art riju slodzi.
English: Renal artery stenosis
Latvian: Nieru art rijas stenoze
English: Diovan has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).
Latvian: Diovan nav p t ts pacientiem ar smagu aknu disfunkciju (skat t apakšpunktus 4.2, 4.3 un 4.4).
English: Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.
Latvian: Td terapijas skum ieteicams veikt nieru funkcijas monitoringu un nodrošint pacienta adekvtu hidratciju.
English: • If you weigh 35 kg or more:
Latvian: • Ja J su erme a masa ir 35 kg vai vair k: